Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
نویسندگان
چکیده
منابع مشابه
Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome*
Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have also been reported. This study reports a case...
متن کاملHematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
BACKGROUND Reductions in transfusion requirements/improvements in hematologic parameters have been associated with iron chelation therapy in transfusion-dependent patients, including those with myelodysplastic syndromes; data on there reductions/improvements have been limited to case reports and small studies. DESIGN AND METHODS To explore this observation in a large population of patients, w...
متن کاملDifferentiation therapy for myelodysplastic syndrome.
Nearly 20 years ago in 1982, one of us wrote a review for Blood about the therapeutic potential of differentiation therapy (1). This was shortly after the initial studies with HL-60 myeloblastic leukemia cells showing that a variety of agents, including retinoids, could induce their terminal differentiation. This was followed by the finding that retinoids, especially ATRA, could cause terminal ...
متن کاملMyelodysplastic Syndrome patients
Large granular lymphocyte leukemia (LGL) is often associated with immune cytopenias and can co-occur in the context of aplastic anemia (AA) and myelodysplastic syndromes (MDS). We took advantage of the recent description of STAT3 mutations in LGL clonal expansions to test, using sensitive methods, for the presence of these mutations in a large cohort of 367 MDS and 140 AA cases. STAT3 clones ca...
متن کاملCONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
BACKGROUND The non-interventional study CONIFER was designed to assess the safety and clinical practicability of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome (MDS) patients. METHODS Patients included in the study were diagnosed with MDS and received at least 1 treatment with deferasirox. The observation period covered the time from the initial visit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Antioxidants
سال: 2019
ISSN: 2076-3921
DOI: 10.3390/antiox8110508